The standard chemotherapy regimen commonly given for Ewing sarcoma is VDCIE, which involves alternating cycles of VDC (vincristine, doxorubicin, cyclophosphamide) and IE (ifosfamide, etoposide). This regimen is typically given every two weeks for six cycles.
Local therapy, whether surgery or radiation, is typically initiated at week 13 in the treatment of Ewing sarcoma, following 12 weeks of upfront chemotherapy.
This video provides a comprehensive overview of Ewing sarcoma, focusing on its characteristics, diagnosis, staging, and treatment. It compares Ewing sarcoma to osteosarcoma, highlights its nature as a small round blue cell tumor and its radiosensitivity, and details the standard treatment approach involving chemotherapy, local therapy (surgery and/or radiation), and consolidation chemotherapy. The video also discusses prognostic factors, staging systems, and key clinical trials guiding management for both localized and metastatic disease.
Ewing sarcoma is highly radiosensitive, whereas osteosarcoma is radioresistant. Treatment for Ewing sarcoma typically involves chemotherapy followed by local control (surgery and/or radiation), while osteosarcoma is primarily managed with surgery followed by chemotherapy, with radiotherapy playing a lesser role. Ewing sarcoma is also considered a small round blue cell tumor, in contrast to osteosarcoma.
The main prognostic factors that predict a poor outcome in Ewing sarcoma can be remembered with the mnemonic "MASSIVE LDH RESPONSE":
| Topic | Tags |
|---|---|
| Ewing Sarcoma Overview | Ewing sarcoma, pediatric sarcoma, bone tumors, small round blue cell tumor, radiosensitivity |
| Ewing Sarcoma vs. Osteosarcoma | Osteosarcoma, comparison, treatment differences, radiosensitivity, location, radiographic hallmarks |
| Ewing Sarcoma Pathophysiology & Genetics | EWSR1 gene, translocation t(11;22), FLI1 gene, t(2;22), EWS gene, ERG gene, chromosomal abnormalities |
| Ewing Sarcoma Epidemiology & Demographics | Peak age, male predominance, common locations (pelvis, extremities), diaphysis, epiphysis, metaphysis, "EGG-NOG" mnemonic |
| Ewing Sarcoma Clinical Presentation | Pain, swelling, mass, limited movement, fever, pathologic fracture, neurological changes, Askin tumor |
| Ewing Sarcoma Staging & Prognosis | Localized vs. metastatic disease, TNM staging, MSTS staging, prognostic factors, "MASSIVE LDH RESPONSE" mnemonic, 5-year survival rates |
| Ewing Sarcoma Workup & Diagnosis | History, physical exam, labs (CBC, CMP, LDH), imaging (X-ray, CT, MRI, PET-CT), biopsy (core biopsy), bone marrow biopsy |
| Ewing Sarcoma Pathology | Histology, CD9, PAS, vimentin, HBA71, beta-2 microglobulin, neural specific enolase, S100, lobular, alveolar, organoid subtypes |
| Ewing Sarcoma Treatment Paradigm | Induction chemotherapy, local therapy, consolidation chemotherapy, VDCIE regimen, surgery, radiation therapy, metastasis-directed therapy |
| Ewing Sarcoma Chemotherapy Regimens | VDC (Vincristine, Doxorubicin, Cyclophosphamide), IE (Ifosfamide, Etoposide), VAC (Vincristine, Actinomycin D, Cyclophosphamide), VAKA IE, dose intensification |
| Ewing Sarcoma Surgery | Resection, negative margins, functional outcomes, expendable bones, reconstruction, definitive radiation vs. debulking surgery |
| Ewing Sarcoma Radiation Therapy | Definitive dose, post-operative dose, dose escalation, pre-operative radiation, concurrent chemo with radiation, toxicity |
| Ewing Sarcoma Clinical Trials (Non-metastatic) | Intergroup 91 trial, AEWS31, AEWS1031, dose comparison, chemotherapy schedules, role of radiation |
| Ewing Sarcoma Clinical Trials (Metastatic) | EOiNG 99, AEWS1221, local therapy to primary and mets, ganotumab (IGF1R antibody) |
| Metastasis-Directed Therapy | Whole lung radiation, radiation boost, management of bone and peritoneal metastases |
